Research publications
- Suetterlin, K., Tan, S., Männikkö, R., Phadke, R., Orford, M.R., Eaton, S., ...Greensmith, L. (2021). Ageing Contributes to Phenotype Transition in a Mouse Model of Periodic Paralysis. Journal of Cachexia, Sarcopenia and Muscle Rapid Communications,
- Suetterlin, K., Männikkö, R., Flossmann, E., Sud, R., Fialho, D., Vivekanandam, V., ...Savvatis, K. (2021). Andersen-Tawil Syndrome Presenting with Complete Heart Block.. J Neuromuscul Dis, doi:10.3233/JND-200572
- Sun, J., Luo, S., Suetterlin, K.J., Song, J., Huang, J., Zhu, W., ...Lu, J. (2021). Clinical and genetic spectrum of a Chinese cohort with SCN4A gene mutations.. Neuromuscular Disorders, doi:10.1016/j.nmd.2021.03.014
- Suetterlin, K., Matthews, E., Sud, R., McCall, S., Fialho, D., Burge, J., ...Kullmann, D.M. (2021). Translating genetic and functional data into clinical practice: a series of 223 families with myotonia..Brain, doi:10.1093/brain/awab344
- Stunnenberg, B., LoRusso, S., Arnold, W.D., Barohn, R.J., Cannon, S.C., Fontaine, B., ...Meola, G. (2020). Guidelines on clinical presentation and management of non-dystrophic myotonias. Muscle & Nerve, doi:10.1002/mus.26887
- Echaniz-Laguna, A., Biancalana, V., Nadaj-Pakleza, A., Fournier, E., Matthews, E., Hanna, M.G., Männikkö, R. (2020). Homozygous C-terminal loss-of-function NaV1.4 variant in a patient with congenital myasthenic syndrome. Journal of Neurology, Neurosurgery & Psychiatry, doi:10.1136/jnnp-2020-323173
- Vivekanandam, V., Mannikko, R., Matthews, E., Hanna, M.G. (2020). Improving genetic diagnostics of skeletal muscle channelopathies. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, doi:10.1080/14737159.2020.1782195
- Veronica Tan, S., Suetterlin, K., Männikkö, R., Matthews, E., Hanna, M.G., Bostock, H. (2020). In vivo assessment of interictal sarcolemmal membrane properties in hypokalaemic and hyperkalaemic periodic paralysis. Clinical Neurophysiology, doi:10.1016/j.clinph.2019.12.414
- Vivekanandam, V., Morrow, J., Matthews, E., Shah, S., Yousry, T., Hanna, M. (2020). Magnetic Resonance Imaging (MRI) in Periodic Paralysis.
- Rayan, D.L.R., Hanna, M.G. (2020). Managing pregnancy and anaesthetics in patients with skeletal muscle channelopathies. NEUROMUSCULAR DISORDERS, 30 (7), 539-545. doi:10.1016/j.nmd.2020.05.007
- Suetterlin, K.J., Raja Rayan, D., Matthews, E., Hanna, M.G. (2020). Mexiletine (NaMuscla) for the treatment of myotonia in non-dystrophic myotonic disorders. Expert Opinion on Orphan Drugs, 1-7. doi:10.1080/21678707.2020.1739519
- Matthews, E., Balestrini, S., Sisodiya, S.M., Hanna, M.G. (2020). Muscle and brain sodium channelopathies: genetic causes, clinical phenotypes, and management approaches. The Lancet Child & Adolescent Health, doi:10.1016/S2352-4642(19)30425-0
- Vivekanandam, V., Munot, P., Hanna, M., Matthews, E. (2020). Skeletal Muscle Channelopathies.Neurologic Clinics, doi:10.1016/j.ncl.2020.04.003
- Cea, G., Andreu, D., Fletcher, E., Ramdas, S., Sud, R., Hanna, M.G., Matthews, E. (2020). Sodium channel myotonia may be associated with high-risk brief resolved unexplained events [version 2; peer review: 2 approved]. Wellcome Open Research, 5 57. doi:10.12688/wellcomeopenres.15798.2
- Suetterlin, K., Vivekanandam, V., James, N., Sud, R., Holmes, S., Fialho, D., ...Matthews, E. (2019). Annual renal ultrasound may prevent acute presentation with acetazolamide-associated urolithiasis.Neurology: Clinical Practice, doi:10.1212/CPJ.0000000000000761
- Vivekanandam, V., Germain, L., Skorupinska, I., Seutterlin, K., Fialho, D., Kozyra, D., ...Hanna, M. (2019). Defining the phenotype of Andersen-Tawil syndrome: the largest reported series.
- Thor, M.G., Vivekanandam, V., Sampedro-Castañeda, M., Tan, S.V., Suetterlin, K., Sud, R., ...Hanna, M.G. (2019). Myotonia in a patient with a mutation in an S4 arginine residue associated with hypokalaemic periodic paralysis and a concomitant synonymous CLCN1 mutation.. Sci Rep, 9 (1), 17560. doi:10.1038/s41598-019-54041-0
- Scalco, R., Morrow, J., Manole, A., Skorupinska, I., Ricciardi, F., Matthews, E., ...Fialho, D. (2019). RCT of 2mg bumetanide for hypokalaemic periodic paralysis.
